The FDA has approved Grastek, a second sublingual immunotherapy to
treat grass pollen allergies. (The first sublingual immunotherapy for
grass allergies, Oralair, was approved earlier this month.) The new
tablet contains Timothy grass extracts and is indicated for patients
aged 5 to 65 years.
In December 2013, FDA advisers called for postapproval studies to test
Grastek’s safety in children aged 5 to 11 years, citing side effects
such as lip swelling and oral blistering.
Reuters story (Free)
By Kristin J. Kelley